Yes, I think that is a real motivation, because it can safely preserve or even advance (competitive differentiator) massive revenues for companies without a strong follow up drug in place or in the works, for those companies. By the time ABL could get to market, they would still have a decade+ to figure out next steps on their runway.

Plus the gradual acceptance of epigenetics over time, as impressive papers keep rolling in, and other companies also advance the epigenetics concept in other areas. 

Who do you think would be the top candidates? Any that are currently working directly with Zenith?

I'm also curious what benefit (if any?) and to whom, ABL has as a standalone drug? Especially given safety, and impact on cytokines and inflammation which could "possibly" be helpful in some other ways, whether in combination for specific issues or just applied to a different set of mild-moderate-severe issues and concerns across many applications and disease states?